Edition:
India

Benitec Biopharma Ltd (BNTC.OQ)

BNTC.OQ on NASDAQ Stock Exchange Capital Market

3.38USD
23 Jan 2018
Change (% chg)

$-0.13 (-3.70%)
Prev Close
$3.51
Open
$3.51
Day's High
$3.51
Day's Low
$3.38
Volume
2,650
Avg. Vol
12,090
52-wk High
$5.48
52-wk Low
$1.55

Latest Key Developments (Source: Significant Developments)

Benitec Biopharma ‍Says U.S. FDA Granted Orphan Drug Designation To BB-301​
Monday, 15 Jan 2018 

Jan 15 (Reuters) - Benitec Biopharma Ltd ::‍U.S. FDA HAS GRANTED ORPHAN DRUG DESIGNATION TO BB-301 FOR TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY(OPMD)​.  Full Article

Benitec Biopharma Posts Qtrly ‍Loss Of A$2.9 mln
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Benitec Biopharma Ltd ::QTRLY ‍LOSS OF A$2.9 MILLION VERSUS PROFIT OF A$0.8 MILLION​.  Full Article

Benitec Biopharma says appoints Jerel Banks as chairman‍​
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Benitec Biopharma Ltd :Appointment of new chairman.Appoints Dr. Jerel Banks as chairman‍​.Jerel Banks replaces Peter Francis as chairman‍​.  Full Article

Benitec Biopharma says Greg West appointed CEO
Wednesday, 10 Aug 2016 

Benitec Biopharma Ltd : Says Bryan Dulhunty appointed CFO .Cliff Holloway appointed CBO and COO.  Full Article

Benitec Biopharma appoints Greg West as chief executive officer
Wednesday, 10 Aug 2016 

Benitec Biopharma Ltd : Restructuring of senior executive team . Says appointment of Greg West as chief executive officer .Bryan Dulhunty appointed as CFO.  Full Article

Benitec Biopharma receives cash refund under government's R&D tax incentive scheme
Thursday, 16 Jun 2016 

Benitec Biopharma Ltd : It has received a $3.6 million cash refund under the federal government's research and development tax incentive scheme .  Full Article

BRIEF-Benitec Biopharma ‍Says U.S. FDA Granted Orphan Drug Designation To BB-301​

* ‍U.S. FDA HAS GRANTED ORPHAN DRUG DESIGNATION TO BB-301 FOR TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY(OPMD)​ Source text for Eikon: Further company coverage: